Site icon pharmaceutical daily

ICE Announces Annual Reconstitution Changes in the ICE Biotechnology Index

ATLANTA & NEW YORK–(BUSINESS WIRE)–Intercontinental Exchange, Inc. (NYSE: ICE), a leading global provider of data, technology and market infrastructure, today announced the annual reconstitution of the ICE Biotechnology Index (ICEBIO), which is effective before the open of trading on Monday, December 20, 2021.

The ICE Biotechnology Index tracks the performance of qualifying U.S. listed biotechnology companies classified within the Biotechnology Sub-Industry Group of the ICE Uniform Sector Classification schema, which is a multi-asset class industry classification taxonomy developed by ICE. The index includes companies that are engaged in the research and development of therapeutic treatments but are not focused on the commercialization and mass production of pharmaceutical drugs. The index also includes companies that are engaged in the production of tools or systems that enable biotechnology processes.

“This annual reconstitution ensures that the index maintains its representation of the broader biotechnology industry,” said Aram Flores, Head of Index and Analytics at ICE. “By including companies meeting a minimum threshold of market capitalization and liquidity from multiple U.S. exchanges, the index provides a better gauge of the biotechnology industry and helps improve the investability for users benchmarking to the index.”

The following companies will be added to and removed from the index in the December 2021 annual reconstitution:

Ticker

Name

Action

ABCL

AbCellera Biologics, Inc.

Addition

ABCM

Abcam PLC Sponsored ADR

Addition

ABOS

Acumen Pharmaceuticals, Inc.

Addition

ABSI

Absci Corporation

Addition

ACET

Adicet Bio Inc

Addition

ACHL

Achilles Therapeutics PLC Sponsored ADR

Addition

ACRS

Aclaris Therapeutics, Inc.

Addition

ADMA

ADMA Biologics, Inc.

Addition

AKUS

Akouos, Inc.

Addition

AKYA

Akoya Biosciences Inc

Addition

ALGS

Aligos Therapeutics, Inc.

Addition

ALPN

Alpine Immune Sciences, Inc.

Addition

ALVR

AlloVir Inc

Addition

AMPE

Ampio Pharmaceuticals, Inc.

Addition

ANVS

Annovis Bio Inc

Addition

ATAI

ATAI Life Sciences N.V.

Addition

ATHA

Athira Pharma, Inc.

Addition

AUPH

Aurinia Pharmaceuticals Inc.

Addition

AUTL

Autolus Therapeutics Plc Sponsored ADR

Addition

AVIR

Atea Pharmaceuticals, Inc.

Addition

AVTE

Aerovate Therapeutics, Inc.

Addition

AVXL

Anavex Life Sciences Corp.

Addition

BCAB

BioAtla, Inc.

Addition

BCYC

Bicycle Therapeutics Plc Sponsored ADR

Addition

BLU

BELLUS Health Inc.

Addition

BMEA

Biomea Fusion Inc

Addition

BNR

Burning Rock Biotech Ltd. Sponsored ADR Class A

Addition

BOLT

Bolt Biotherapeutics, Inc.

Addition

BTX

Brooklyn ImmunoTherapeutics, Inc.

Addition

CADL

Candel Therapeutics, Inc.

Addition

CCCC

C4 Therapeutics, Inc.

Addition

CDAK

Codiak BioSciences, Inc.

Addition

CGEM

Cullinan Oncology, Inc.

Addition

CLSD

Clearside Biomedical, Inc.

Addition

CMPS

COMPASS Pathways Plc Sponsored ADR

Addition

CMRX

Chimerix, Inc.

Addition

CNTA

Centessa Pharmaceuticals PLC ADR

Addition

CNTB

Connect Biopharma Holdings Ltd. Sponsored ADR

Addition

CRBU

Caribou Biosciences, Inc.

Addition

CRIS

Curis, Inc.

Addition

CTKB

Cytek Biosciences, Inc.

Addition

CVAC

CureVac N.V.

Addition

CYBN

Cybin, Inc.

Addition

CYT

Cyteir Therapeutics, Inc.

Addition

DAWN

Day One Biopharmaceuticals, Inc.

Addition

DBTX

Decibel Therapeutics, Inc.

Addition

DBVT

DBV Technologies SA Sponsored ADR

Addition

DNAY

Codex DNA, Inc.

Addition

DSGN

Design Therapeutics, Inc.

Addition

DYN

Dyne Therapeutics Inc

Addition

ERAS

Erasca, Inc.

Addition

ETNB

89bio Inc

Addition

EVLO

Evelo Biosciences, Inc.

Addition

EWTX

Edgewise Therapeutics, Inc.

Addition

FDMT

4D Molecular Therapeutics, Inc.

Addition

GLUE

Monte Rosa Therapeutics, Inc.

Addition

GRCL

Gracell Biotechnologies Inc. Sponsored ADR Class A

Addition

GRPH

Graphite Bio, Inc.

Addition

GRTS

Gritstone bio, Inc.

Addition

GTH

Genetron Holdings Ltd Sponsored ADR

Addition

HBIO

Harvard Bioscience, Inc.

Addition

HOWL

Werewolf Therapeutics, Inc.

Addition

HUMA

Humacyte, Inc.

Addition

ICVX

Icosavax, Inc.

Addition

IKNA

Ikena Oncology, Inc.

Addition

IMGO

Imago BioSciences, Inc.

Addition

IMMP

Immutep Ltd Sponsored ADR

Addition

IMPL

Impel NeuroPharma, Inc.

Addition

IMRX

Immuneering Corp. Class A

Addition

INBX

Inhibrx Inc

Addition

INFI

Infinity Pharmaceuticals, Inc.

Addition

IPHA

Innate Pharma SA Sponsored ADR

Addition

IPSC

Century Therapeutics, Inc.

Addition

JANX

Janux Therapeutics, Inc.

Addition

KMDA

Kamada Ltd

Addition

KMPH

KemPharm, Inc.

Addition

KNTE

Kinnate Biopharma, Inc.

Addition

KRON

Kronos Bio Inc

Addition

KYMR

Kymera Therapeutics, Inc.

Addition

LABP

Landos Biopharma, Inc.

Addition

LCTX

Lineage Cell Therapeutics, Inc.

Addition

LPTX

Leap Therapeutics, Inc.

Addition

LYEL

Lyell Immunopharma, Inc.

Addition

MBIO

Mustang Bio, Inc.

Addition

MIRM

Mirum Pharmaceuticals, Inc.

Addition

MORF

Morphic Holding, Inc.

Addition

MREO

Mereo BioPharma Group plc Sponsored ADR

Addition

MRUS

Merus N.V.

Addition

MRVI

Maravai LifeSciences Holdings Inc Class A

Addition

MTEM

Molecular Templates, Inc.

Addition

MTNB

Matinas BioPharma Holdings, Inc.

Addition

MXCT

MaxCyte, Inc.

Addition

NAUT

Nautilus Biotechnolgy, Inc.

Addition

NRXP

NRX Pharmaceuticals, Inc.

Addition

NUVB

Nuvation Bio Inc Class A

Addition

NUVL

Nuvalent, Inc. Class A

Addition

OBSV

ObsEva SA

Addition

OCX

Oncocyte Corporation

Addition

OLK

Olink Holding AB Sponsored ADR

Addition

OLMA

Olema Pharmaceuticals, Inc.

Addition

OMGA

Omega Therapeutics, Inc.

Addition

OMIC

Singular Genomics Systems, Inc.

Addition

ONCR

Oncorus, Inc.

Addition

OYST

Oyster Point Pharma Inc

Addition

PCVX

Vaxcyte, Inc.

Addition

PHAT

Phathom Pharmaceuticals, Inc.

Addition

PMVP

PMV Pharmaceuticals, Inc.

Addition

PRAX

Praxis Precision Medicines, Inc.

Addition

PRLD

Prelude Therapeutics, Inc.

Addition

PRQR

ProQR Therapeutics N.V.

Addition

RAIN

Rain Therapeutics Inc

Addition

RANI

Rani Therapeutics Holdings, Inc. Class A

Addition

RLYB

Rallybio Corporation

Addition

ROIV

Roivant Sciences Ltd.

Addition

RXDX

Prometheus Biosciences, Inc

Addition

RXRX

Recursion Pharmaceuticals, Inc Class A

Addition

SANA

Sana Biotechnology, Inc.

Addition

SBTX

Silverback Therapeutics, Inc.

Addition

SEER

Seer, Inc. Class A

Addition

SESN

Sesen Bio, Inc.

Addition

SLDB

Solid Biosciences Inc.

Addition

SMMT

Summit Therapeutics Inc

Addition

SNSE

Sensei Biotherapeutics, Inc.

Addition

SQZ

SQZ Biotechnologies Company

Addition

STTK

Shattuck Labs, Inc.

Addition

STVN

Stevanato Group SpA

Addition

SYNH

Syneos Health, Inc. Class A

Addition

TALS

Talaris Therapeutics, Inc.

Addition

TERN

Terns Pharmaceuticals, Inc.

Addition

TIL

Instil Bio, Inc.

Addition

TKNO

Alpha Teknova, Inc.

Addition

TNYA

Tenaya Therapeutics, Inc.

Addition

TSHA

Taysha Gene Therapies, Inc.

Addition

VERV

Verve Therapeutics, Inc.

Addition

VIRX

Viracta Therapeutics, Inc.

Addition

VOR

Vor Biopharma, Inc.

Addition

VRCA

Verrica Pharmaceuticals Inc.

Addition

AMRS

Amyris, Inc.

Deletion

APRE

Aprea Therapeutics, Inc.

Deletion

ARDX

Ardelyx, Inc.

Deletion

ASMB

Assembly Biosciences, Inc.

Deletion

BCEL

Atreca, Inc. Class A

Deletion

CALA

Calithera Biosciences, Inc.

Deletion

CERS

Cerus Corporation

Deletion

CNCE

Concert Pharmaceuticals, Inc.

Deletion

EGRX

Eagle Pharmaceuticals, Inc.

Deletion

ESPR

Esperion Therapeutics, Inc.

Deletion

GH

Guardant Health, Inc.

Deletion

INZY

Inozyme Pharma, Inc.

Deletion

KALA

Kala Pharmaceuticals, Inc.

Deletion

KLDO

Kaleido Biosciences, Inc.

Deletion

MNOV

MediciNova, Inc.

Deletion

MOR

MorphoSys AG Sponsored ADR

Deletion

NCNA

NuCana plc Sponsored ADR

Deletion

ODT

Odonate Therapeutics, Inc.

Deletion

OMER

Omeros Corporation

Deletion

SIGA

SIGA Technologies Inc

Deletion

SUPN

Supernus Pharmaceuticals, Inc.

Deletion

TLSA

Tiziana Life Sciences Ltd.

Deletion

UBX

Unity Biotechnology, Inc.

Deletion

VRNA

Verona Pharma plc Sponsored ADR

Deletion

VYGR

Voyager Therapeutics, Inc.

Deletion

XBIT

XBiotech, Inc.

Deletion

ICE’s global family of indices serve as the performance benchmark for more than $1 trillion in assets managed by investors around the globe. For more information about ICE’s Indices, please visit: https://www.ice.com/market-data/indices.

About Intercontinental Exchange

Intercontinental Exchange, Inc. (NYSE: ICE) is a Fortune 500 company that designs, builds and operates digital networks to connect people to opportunity. We provide financial technology and data services across major asset classes that offer our customers access to mission-critical workflow tools that increase transparency and operational efficiencies. We operate exchanges, including the New York Stock Exchange, and clearing houses that help people invest, raise capital and manage risk across multiple asset classes. Our comprehensive fixed income data services and execution capabilities provide information, analytics and platforms that help our customers capitalize on opportunities and operate more efficiently. At ICE Mortgage Technology, we are transforming and digitizing the U.S. residential mortgage process, from consumer engagement through loan registration. Together, we transform, streamline and automate industries to connect our customers to opportunity.

Trademarks of ICE and/or its affiliates include Intercontinental Exchange, ICE, ICE block design, NYSE and New York Stock Exchange. Information regarding additional trademarks and intellectual property rights of Intercontinental Exchange, Inc. and/or its affiliates is located here. Key Information Documents for certain products covered by the EU Packaged Retail and Insurance-based Investment Products Regulation can be accessed on the relevant exchange website under the heading “Key Information Documents (KIDS).”

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 — Statements in this press release regarding ICE’s business that are not historical facts are “forward-looking statements” that involve risks and uncertainties. For a discussion of additional risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see ICE’s Securities and Exchange Commission (SEC) filings, including, but not limited to, the risk factors in ICE’s Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the SEC on February 4, 2021.

SOURCE: Intercontinental Exchange

ICE-CORP

Contacts

ICE Media Contact:

Damon Leavell

damon.leavell@ice.com
(212) 323-8587

media@ice.com

ICE Investor Contact:

Mary Caroline O’Neal

marycaroline.oneal@ice.com
(770) 738-2151

investors@ice.com

Exit mobile version